Erratum
for
Monk et al., J Clin Oncol 23 (21) 4617-4625.
Journal of Clinical Oncology, Vol 23, No 33 (November 20), 2005: pp. 8549
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.10.902
ERRATA
The July 20, 2005, article by Monk et al titled, "Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group Study" (J Clin Oncol 23:4617-4625, 2005) contained an error.
In the Results section, under the heading "Relationship Between QOL and Missing Assessments," the second to last sentence read:
Figure 1 showed that patients with better QOL (relative to the FACT-G and Cx subscale) and worse adverse effects (relative to the NTX subscale and BPI) were more likely to complete subsequent QOL assessments.
Whereas it should have read:
Figure 1 showed that patients with better QOL (relative to the FACT-G and Cx subscale) and less adverse effects (relative to the NTX subscale and BPI) were more likely to complete subsequent QOL assessments.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
|